DK2582794T4 - Generering af inducerede pluripotente stamceller fra små volumener af perifert blod - Google Patents

Generering af inducerede pluripotente stamceller fra små volumener af perifert blod Download PDF

Info

Publication number
DK2582794T4
DK2582794T4 DK11796290.2T DK11796290T DK2582794T4 DK 2582794 T4 DK2582794 T4 DK 2582794T4 DK 11796290 T DK11796290 T DK 11796290T DK 2582794 T4 DK2582794 T4 DK 2582794T4
Authority
DK
Denmark
Prior art keywords
generation
stem cells
peripheral blood
pluripotent stem
induced pluripotent
Prior art date
Application number
DK11796290.2T
Other languages
English (en)
Other versions
DK2582794T3 (da
Inventor
Amanda Mack
Original Assignee
Fujifilm Cellular Dynamics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348816&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2582794(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujifilm Cellular Dynamics Inc filed Critical Fujifilm Cellular Dynamics Inc
Publication of DK2582794T3 publication Critical patent/DK2582794T3/da
Application granted granted Critical
Publication of DK2582794T4 publication Critical patent/DK2582794T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/98—Xeno-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK11796290.2T 2010-06-15 2011-06-14 Generering af inducerede pluripotente stamceller fra små volumener af perifert blod DK2582794T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35504610P 2010-06-15 2010-06-15
US38894910P 2010-10-01 2010-10-01
PCT/US2011/040323 WO2011159684A2 (en) 2010-06-15 2011-06-14 Generation of induced pluripotent stem cells from small volumes of peripheral blood

Publications (2)

Publication Number Publication Date
DK2582794T3 DK2582794T3 (da) 2018-05-22
DK2582794T4 true DK2582794T4 (da) 2024-07-22

Family

ID=45348816

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11796290.2T DK2582794T4 (da) 2010-06-15 2011-06-14 Generering af inducerede pluripotente stamceller fra små volumener af perifert blod

Country Status (11)

Country Link
US (4) US8691574B2 (da)
EP (2) EP2582794B2 (da)
JP (4) JP5984217B2 (da)
KR (1) KR101861168B1 (da)
CN (1) CN103003416B (da)
AU (1) AU2011267849B2 (da)
CA (1) CA2802249A1 (da)
DK (1) DK2582794T4 (da)
ES (1) ES2670842T3 (da)
IL (1) IL223527B (da)
WO (1) WO2011159684A2 (da)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101811235B1 (ko) 2009-06-05 2017-12-21 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 Ｔ 세포 및 조혈 세포의 재프로그래밍
JP5984217B2 (ja) * 2010-06-15 2016-09-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
KR102482184B1 (ko) * 2010-12-22 2022-12-28 페이트 세러퓨틱스, 인코포레이티드 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼
WO2013177228A1 (en) * 2012-05-22 2013-11-28 Loma Linda University Generation of integration/transgene-free stem cells
EP2914728B1 (en) * 2012-11-01 2020-07-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
US20150247125A1 (en) * 2012-11-02 2015-09-03 Lonza Walkersville Micrornas and cellular reprogramming
CN103088065B (zh) * 2013-01-25 2014-12-10 北京银杏德济生物技术有限公司 一种能够大规模并快速高纯度地诱导间充质干细胞转决定成造血干细胞的方法
ES2491491B1 (es) * 2013-03-05 2015-06-16 Vodafone España, S.A.U. Método para asociar de manera anónima mediciones de un dispositivo de monitorización sanitaria con un ID de usuario
JP6689498B2 (ja) * 2013-04-16 2020-04-28 イーエムべーアー−インスティツート フューア モレクラー ビオテクノロギー ゲーエムベーハー ブラストイド、細胞株に基づく人工胚盤胞
WO2014201154A1 (en) * 2013-06-14 2014-12-18 Microstem, Inc. Matrix combinations support hematopoietic stem cell in vitro culturing
WO2015006725A2 (en) 2013-07-12 2015-01-15 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells from normal human mammary epithelial cells
KR101655383B1 (ko) * 2013-07-27 2016-09-08 고려대학교 산학협력단 소분자 화합물을 포함하는 만능성 줄기세포의 염색체 안정성 유지용 조성물
EP3604499A1 (en) 2014-03-04 2020-02-05 Fate Therapeutics, Inc. Improved reprogramming methods and cell culture platforms
CN106471118A (zh) * 2014-03-11 2017-03-01 新加坡科技研究局 在造血细胞中诱导多能性的方法
US10023879B2 (en) 2014-06-04 2018-07-17 Fate Therapeutics, Inc. Minimal volume reprogramming of mononuclear cells
EP3786285A1 (en) * 2014-06-05 2021-03-03 Cedars-Sinai Medical Center A novel and efficient method for reprogramming immortalized lymphoblastoid cell lines to induced pluripotent stem cells
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
EP3280426A2 (en) * 2015-04-09 2018-02-14 Biolamina AB Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases
KR20180042437A (ko) 2015-09-08 2018-04-25 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 임상 등급 망막 색소 상피 세포의 재현성 있는 분화 방법
DK3347457T3 (da) 2015-09-08 2022-01-17 Fujifilm Cellular Dynamics Inc MACS-baseret oprensning af stamcelleafledt retinalt pigmentepitel
US9509684B1 (en) * 2015-10-14 2016-11-29 FullArmor Corporation System and method for resource access with identity impersonation
US9762563B2 (en) 2015-10-14 2017-09-12 FullArmor Corporation Resource access system and method
US9450944B1 (en) 2015-10-14 2016-09-20 FullArmor Corporation System and method for pass-through authentication
AU2016338680B2 (en) 2015-10-16 2022-11-17 Fate Therapeutics, Inc. Platform for the induction and maintenance of ground state pluripotency
US10947502B2 (en) * 2015-10-20 2021-03-16 FUJIFILM Cellular Dynamics, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
AU2016349504B2 (en) 2015-11-04 2023-02-09 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
AU2016348342B2 (en) 2015-11-04 2023-07-06 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
AU2017290805B2 (en) 2016-07-01 2023-11-16 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
WO2018048828A1 (en) 2016-09-06 2018-03-15 The Children's Medical Center Corporation Immune cells derived from induced pluripotent stem cell
AU2017340634B2 (en) 2016-10-05 2022-06-02 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with MECP2 disruption
KR102558606B1 (ko) 2016-12-05 2023-07-26 칠드런즈 호스피탈 메디칼 센터 결장 유사장기 및 이를 제조 및 사용하는 방법
US20200040309A1 (en) * 2017-04-14 2020-02-06 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
EA201992469A1 (ru) * 2017-04-18 2020-05-27 Фуджифилм Селльюлар Дайнамикс, Инк. Антигенспецифические иммунные эффекторные клетки
WO2018217567A1 (en) * 2017-05-22 2018-11-29 Transfusion Health, Llc Compositions and methods of making expanded hematopoietic stem cells using pten inhibitors
GB201708554D0 (en) * 2017-05-30 2017-07-12 Queens Univ Of Belfast A method for the generation of induced pluirpotent stem cells
CN107245474A (zh) * 2017-06-07 2017-10-13 北京呈诺医学科技有限公司 一种无饲养层无血清的人类诱导性多能干细胞分离培养方法
US11572544B2 (en) 2017-06-14 2023-02-07 The Children's Medical Center Corporation Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer
WO2019084452A1 (en) 2017-10-27 2019-05-02 Transfusion Health, Llc COMPOSITIONS AND METHODS FOR PRODUCING EXPANDED HEMATOPOIETIC STEM CELLS USING FLUORENE DERIVATIVES
AU2019386140A1 (en) 2018-11-28 2021-06-24 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
US20220033778A1 (en) 2018-11-29 2022-02-03 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
WO2020203712A1 (ja) 2019-03-29 2020-10-08 富士フイルム株式会社 特定細胞に分化する能力を有する多能性幹細胞の製造方法およびその応用
WO2020223303A1 (en) * 2019-04-29 2020-11-05 The Children's Hospital Of Philadelphia Compositions and methods for increasing megakaryocyte production
WO2021085033A1 (ja) 2019-10-28 2021-05-06 富士フイルム株式会社 多能性幹細胞の選別方法、分化誘導結果の予測方法及び細胞製品の製造方法
WO2021085034A1 (ja) 2019-10-28 2021-05-06 富士フイルム株式会社 多能性幹細胞の選別方法、分化誘導結果の予測方法及び細胞製品の製造方法
CN110669732B (zh) * 2019-11-05 2021-05-04 清华大学 组合物在将造血祖细胞重编程为造血干细胞中的用途
WO2021145402A1 (ja) 2020-01-16 2021-07-22 富士フイルム株式会社 特定細胞に分化する能力を有する多能性幹細胞の製造方法およびその応用
AU2021211713A1 (en) 2020-01-23 2022-08-25 The Children's Medical Center Corporation Stroma-free T cell differentiation from human pluripotent stem cells
WO2021216114A1 (en) 2020-04-22 2021-10-28 Houston Gene Therapeutics Llc Compositions for treatment of vascular disease
CN115885048A (zh) 2020-06-19 2023-03-31 富士胶片株式会社 生物标记确定方法及细胞的制造方法
EP4172319A4 (en) * 2020-06-23 2024-08-28 Tithon Biotech Inc SMALL PLURIPOTENT CELLS DERIVED FROM PERIPHERAL BLOOD
BR112022026899A2 (pt) 2020-07-20 2023-01-24 Enanta Pharm Inc Composto representado pela fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método de tratamento ou prevenção de uma infecção por vírus, método de inibição da protease 3c viral ou protease 3cl viral em um mamífero e método de tratamento de um distúrbio respiratório
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022109360A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11384090B2 (en) 2020-11-23 2022-07-12 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11352363B1 (en) 2020-11-23 2022-06-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
AU2021388155A1 (en) 2020-11-25 2023-06-15 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
US11319325B1 (en) 2021-05-11 2022-05-03 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US11339170B1 (en) 2021-07-23 2022-05-24 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11325916B1 (en) 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CA3231501A1 (en) 2021-09-13 2023-03-16 Steven Kattman Methods for the production of committed cardiac progenitor cells
WO2023053220A1 (ja) 2021-09-28 2023-04-06 公益財団法人京都大学ｉＰＳ細胞研究財団 多能性幹細胞の製造方法
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023086352A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
CN114958771B (zh) * 2022-06-27 2023-12-05 广东康盾创新产业集团股份公司 一种ipsc-car-nk细胞的制备方法
WO2024073776A1 (en) 2022-09-30 2024-04-04 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4714680B1 (en) 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
KR0133372B1 (ko) 1991-09-06 1998-04-23 고야 다다시 4-아미노(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5591616A (en) 1992-07-07 1997-01-07 Japan Tobacco, Inc. Method for transforming monocotyledons
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
JP2952041B2 (ja) 1992-07-27 1999-09-20 パイオニア ハイ−ブレッド インターナショナル，インコーポレイテッド 培養ダイズ細胞のａｇｒｏｂａｃｔｅｒｉｕｍ媒介形質転換の改良法
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
JPH09502167A (ja) 1993-07-29 1997-03-04 システミックス，インコーポレイテッド 新規な幹細胞マーカー
EP0722331A4 (en) 1993-08-25 1997-10-01 Systemix Inc METHOD FOR PRODUCING A POPULATION OF HIGHLY ENRICHED HEMATOPOIETIC STEM CELLS
EP0736169A4 (en) 1993-09-17 1998-06-10 Systemix Inc PROCESS FOR PRODUCING CELL POPULATION ENRICHED IN STEM CELLS AND COMPOSITIONS DERIVED THEREFROM
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5824547A (en) 1994-11-29 1998-10-20 Takara Shuzo Co., Ltd. Method for production of transfected cells
US5728581A (en) 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US20030059913A1 (en) 1995-11-20 2003-03-27 Walter Weyler Novel Microorganisms with ability to degrade indole and novel enzymes therefrom
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
ATE245424T1 (de) * 1996-03-14 2003-08-15 Univ Alberta Verwendung von hyaluronsäure zur zellmobilisierung
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
AU5734998A (en) 1997-01-10 1998-08-03 Life Technologies, Inc. Embryonic stem cell serum replacement
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
WO1999020741A1 (en) 1997-10-23 1999-04-29 Geron Corporation Methods and materials for the growth of primate-derived primordial stem cells
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
EP1179049A2 (en) 1999-05-14 2002-02-13 City of Hope (ex vivo) expansion of mammalian hematopoietic stem cells
JP2002184539A (ja) 2000-12-14 2002-06-28 Auto Network Gijutsu Kenkyusho:Kk コネクタ
ATE325795T1 (de) 2001-03-23 2006-06-15 Bayer Corp Rho-kinase inhibitoren
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
JPWO2002100889A1 (ja) 2001-06-08 2004-09-24 麒麟麦酒株式会社 ヒトパピローマウイルスｅ７抗原の新規エピトープおよびそのエピトープにより活性化されたｃｄ４陽性ｔ細胞
US20030211603A1 (en) 2001-08-14 2003-11-13 Earp David J. Reprogramming cells for enhanced differentiation capacity using pluripotent stem cells
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
EP2361966A1 (en) 2002-05-17 2011-08-31 Mount Sinai School of Medicine of New York University Mesoderm and definitive endoderm cell populations
US20040039796A1 (en) 2002-08-08 2004-02-26 Virtual Radio, Inc. Personalized cyber disk jockey and Internet radio advertising
WO2004039796A1 (de) 2002-10-28 2004-05-13 Bayer Healthcare Ag Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
US7986994B2 (en) 2002-12-04 2011-07-26 Medtronic, Inc. Method and apparatus for detecting change in intrathoracic electrical impedance
US20050123902A1 (en) 2003-05-21 2005-06-09 President And Fellows Of Harvard College Human papillomavirus inhibitors
AU2005221079B2 (en) 2004-03-10 2010-07-22 Regents Of The University Of California Compositions and methods for growth of embryonic stem cells
US7452718B2 (en) 2004-03-26 2008-11-18 Geron Corporation Direct differentiation method for making cardiomyocytes from human embryonic stem cells
US8492147B2 (en) 2004-06-18 2013-07-23 Riken Method of inducing the differentiation of embryonic stem cells into nerve by serum-free suspension culture
US20080038820A1 (en) 2004-06-22 2008-02-14 Rudy-Reil Diane E Induction of pluripotent stem cells into mesodermal lineages
WO2006029198A2 (en) 2004-09-08 2006-03-16 Wisconsin Alumni Research Foundation Culturing human embryonic stem cells
US20080254003A1 (en) 2004-12-22 2008-10-16 Robert Passier Differentiation of Human Embryonic Stem Cells and Cardiomyocytes and Cardiomyocyte Progenitors Derived Therefrom
US7606580B2 (en) 2005-05-11 2009-10-20 Aol Llc Personalized location information for mobile devices
US7599295B2 (en) 2005-09-20 2009-10-06 Futurewei Technologies, Inc. System for passive alarm propagation and suppression for packet based networks
US20070116680A1 (en) 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
ATE530637T1 (de) 2006-03-30 2011-11-15 Univ Edinburgh Kulturmedium mit kinasehemmern und verwendung
MX2009000285A (es) 2006-06-30 2009-06-08 Schering Corp Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
JP4960450B2 (ja) 2006-07-14 2012-06-27 ノバルティス アーゲー Ａｌｋ−５阻害剤としてのピリミジン誘導体
WO2008094597A2 (en) 2007-01-30 2008-08-07 University Of Georgia Research Foundation, Inc. Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (mmc)
SG193653A1 (en) 2007-03-23 2013-10-30 Wisconsin Alumni Res Found Somatic cell reprogramming
CN101100655B (zh) * 2007-06-15 2011-08-03 中国人民解放军第二军医大学 胚胎源性多能干细胞向心脏起搏细胞定向诱导分化的方法
WO2009032456A2 (en) 2007-08-01 2009-03-12 Primegen Biotech Llc Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
WO2009091543A1 (en) 2008-01-14 2009-07-23 Lindner Scott E An efficient orip/ebna-1 plasmid vector
JP2011160661A (ja) * 2008-06-02 2011-08-25 Kyowa Hakko Kirin Co Ltd 血球細胞の初期化法
US8546140B2 (en) 2008-06-04 2013-10-01 Cellular Dynamics International, Inc. Methods for the production of iPS cells using non-viral approach
DE102008040322A1 (de) 2008-07-10 2010-09-16 Dilo Trading Ag Energiespeicher-Kreislaufsystem unter Verwendung von Lithium-Ionen-Zellen
US8288513B2 (en) 2008-07-25 2012-10-16 Becton, Dickinson And Company Defined cell culturing surfaces and methods of use
CA2697621C (en) * 2008-07-30 2017-01-17 Kyoto University Method of efficiently establishing induced pluripotent stem cells
JP2012500005A (ja) 2008-08-12 2012-01-05 セルラー ダイナミクス インターナショナル， インコーポレイテッド ｉＰＳ細胞を生成するための方法
US8268620B2 (en) † 2008-10-24 2012-09-18 Wisconsin Alumni Research Foundation OCT4 and SOX2 with SV40 T antigen produce pluripotent stem cells from primate somatic cells
WO2010099539A1 (en) 2009-02-27 2010-09-02 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
JP5633075B2 (ja) † 2009-05-18 2014-12-03 独立行政法人産業技術総合研究所 多能性幹細胞作成用ベクター材料及びこれを用いた多能性幹細胞作成方法
US8496941B2 (en) 2009-06-03 2013-07-30 National Institute Of Advanced Industrial Science And Technology Vectors for generating pluripotent stem cells and methods of producing pluripotent stem cells using the same
KR101811235B1 (ko) * 2009-06-05 2017-12-21 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 Ｔ 세포 및 조혈 세포의 재프로그래밍
SG10201608797WA (en) * 2009-08-07 2016-12-29 Univ Kyoto Method of efficiently establishing induced pluripotent stem cells
CN102803476A (zh) 2009-09-14 2012-11-28 程临钊 血细胞重编程产生多潜能干细胞和多功能干细胞
EP2496689B1 (en) 2009-11-04 2015-05-20 Cellular Dynamics International, Inc. Episomal reprogramming with chemicals
US8048675B1 (en) 2010-05-12 2011-11-01 Ipierian, Inc. Integration-free human induced pluripotent stem cells from blood
JP5984217B2 (ja) * 2010-06-15 2016-09-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
US9409760B1 (en) 2013-12-05 2016-08-09 Paul Lichtefeld, Sr. Fluid dispenser
US9410501B2 (en) 2014-04-25 2016-08-09 Rohr, Inc. Translating sleeve actuation system and apparatus

Also Published As

Publication number Publication date
EP2582794B1 (en) 2018-03-07
US10260048B2 (en) 2019-04-16
JP5984217B2 (ja) 2016-09-06
KR20130087009A (ko) 2013-08-05
AU2011267849B2 (en) 2015-02-05
DK2582794T3 (da) 2018-05-22
KR101861168B1 (ko) 2018-05-31
JP2018019725A (ja) 2018-02-08
JP2021035399A (ja) 2021-03-04
US9447382B2 (en) 2016-09-20
US20240228977A1 (en) 2024-07-11
JP2013528397A (ja) 2013-07-11
JP2015211695A (ja) 2015-11-26
US20140234973A1 (en) 2014-08-21
EP2582794A2 (en) 2013-04-24
US8691574B2 (en) 2014-04-08
EP2582794B2 (en) 2024-04-24
WO2011159684A2 (en) 2011-12-22
AU2011267849A1 (en) 2013-01-10
ES2670842T3 (es) 2018-06-01
CN103003416A (zh) 2013-03-27
CA2802249A1 (en) 2011-12-22
WO2011159684A3 (en) 2012-04-19
CN103003416B (zh) 2016-11-16
EP3382008A1 (en) 2018-10-03
US20120009676A1 (en) 2012-01-12
IL223527B (en) 2018-05-31
US20170088818A1 (en) 2017-03-30
EP2582794A4 (en) 2013-12-11

Similar Documents

Publication Publication Date Title
DK2582794T4 (da) Generering af inducerede pluripotente stamceller fra små volumener af perifert blod
CY2019031I2 (el) Αναπνευστικη απελευθερωση ενεργων παραγοντων
FI20105825A0 (fi) Veriryhmästatuksen käyttö III
DK3498225T3 (da) Hjerteklapprotese
DK3214170T3 (da) Pluripotent stamcelle, der kan isoleres fra kropsvæv
DK2516625T3 (da) Differentiering af humane embryonale stamceller
DK2456853T3 (da) Anvendelse af stamceller til reduktion af leukocyt-ekstravasation
DK2542189T3 (da) Håndprotese
DK2569154T3 (da) Flerlags støbt legeme af træfiner
BR112013012217A2 (pt) incubadora
IL217063A0 (en) Generation of induced pluripotent stem cells from cord blood
BRPI0913925A2 (pt) Diferenciação de células-tronco pluripotentes
IT1403453B1 (it) Protesi retinica
EP2531853A4 (en) USE OF NEW MARKERS OF PLURIPOTENT STEM CELLS
IL221586B (en) Smooth muscle-like cells (smlcs) derived from human pluripotent stem cells
FI20096402A0 (fi) Veriryhmästatuksen käyttö II
DK2590565T3 (da) Blodprøvetagning
HK1203551A1 (en) Induced pluripotent stem cells prepared from human kidney-derived cells
BR112012001107A2 (pt) Células derivadas de tecido cardíaco
IT1398664B1 (it) Protesi con risposta biologica differenziata
DK2566505T3 (da) Fremføring af kolesterylester til steroidogene væv
UY33136A (es) Tropinonabencilaminas como inhibidores de la beta-triptasa
FI20095792A (fi) Ihmissolujen käyttö
FI20105824A0 (fi) Veriryhmästatuksen käyttö IV
FR2956099B1 (fr) Contenant gerbable du type poubelle